Terms: = Lymphoma AND SRSF2, Q01130, 6427, SFRS2 AND Prognosis
5 results:
1. Wilms' tumor 1 expression combined with genetic mutations for prognostic assessment in MDS.
Pan D; Zhao W; Jiang Q; Yin C; He H; Liao L; Ye J; Dai M
Leuk Lymphoma; 2023 Apr; 64(4):856-864. PubMed ID: 36905177
[TBL] [Abstract] [Full Text] [Related]
2. The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.
Xu J; Hao Z; Chen X; Hong M; Muyey DM; Chen X; Wang H
Leuk Lymphoma; 2022 Oct; 63(10):2321-2329. PubMed ID: 35652795
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Markers and prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis.
Lee YC; Hsieh CC; Lee YL; Li CY
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):558-568. PubMed ID: 29970342
[TBL] [Abstract] [Full Text] [Related]
4. prognosis of Primary Myelofibrosis in the Genomic Era.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
[TBL] [Abstract] [Full Text] [Related]
5. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
[TBL] [Abstract] [Full Text] [Related]
